Immunotherapy
News
Prescient Therapeutics unveils three new development programs
Australian clinical stage biotech company Prescient Therapeutics (ASX: PTX) will undertake three internal development programs to advance its
Webcast
Prescient Therapeutics Investor Briefing – 4 November
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers through universal CAR-T
News
Prescient Therapeutics – Interview with Dr Allen Ebens
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving to be a
News
Prescient Therapeutics adds Peter Mac collaboration to CAR-T focus
Australian listed biotechnology company Prescient Therapeutics (ASX: PTX) today updated the market on progress on one of its
News
PTX in pole position as race to cure cancer heats up
Australian listed biotechnology company Prescient Therapeutics (ASX: PTX) today updated the market on progress on one of its
News
Aussie biotech aims high in race to cure cancer
Every year 45,000 of the most respected professionals in oncology gather at the American Society of Clinical Oncology